» Articles » PMID: 39351390

The Impact of Cardiovascular Events in Bronchiectasis: a Systematic Review and Meta-analysis

Abstract

Background: Bronchiectasis is a chronic respiratory condition characterised by airway and systemic inflammation with prevalence increasing with age. Given the median age of the patients, it is common to observe the presence of comorbidities, particularly cardiovascular diseases, which have been linked to adverse clinical outcomes. To investigate the pooled estimates of the association between bronchiectasis and coronary heart disease or stroke within this population, we conducted a systematic review and meta-analysis of the available scientific evidence.

Methods: Three investigators independently performed the search on PubMed and other sources and included studies published up to October 2023 according to predefined criteria. Relative measures of association between bronchiectasis and cardiovascular events were pooled and meta-analysed using a fixed-effects model. Studies were evaluated using the Newcastle-Ottawa Scale for assessing the quality of non-randomised studies in meta-analyses.

Results: A final pool of nine studies was included in the systematic review, with a total of 22 239 patients. Meta-analysis of three high-quality cohort studies showed a pooled hazard ratio of 1.42 (95% CI 1.30-1.57) for coronary heart disease and 1.71 (95% CI 1.55-1.89) for cerebrovascular stroke.

Conclusions: The increased cardiovascular risk among people with bronchiectasis underscores the critical need to raise awareness of this association and to develop preventive strategies accordingly. Further translational studies are imperative to gain a deeper understanding of the complex interplay between inflammation, the immune system and endothelial dysfunction in this patient group.

Citing Articles

Unravelling the role of heart rate recovery in bronchiectasis: do we need to establish a cutoff value?.

Spinou A, Laoutaris I ERJ Open Res. 2025; 11(2).

PMID: 40040891 PMC: 11873879. DOI: 10.1183/23120541.01119-2024.

References
1.
Diel R, Ewig S, Blaas S, Jacob C, Juelich F, Korfmann G . Incidence of patients with non-cystic fibrosis bronchiectasis in Germany - A healthcare insurance claims data analysis. Respir Med. 2019; 151:121-127. DOI: 10.1016/j.rmed.2019.04.007. View

2.
Chen S, Qiu A, Tao Z, Zhang H . Clinical impact of cardiovascular disease on patients with bronchiectasis. BMC Pulm Med. 2020; 20(1):101. PMC: 7181495. DOI: 10.1186/s12890-020-1137-7. View

3.
McDonnell M, Aliberti S, Goeminne P, Restrepo M, Finch S, Pesci A . Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016; 4(12):969-979. PMC: 5369638. DOI: 10.1016/S2213-2600(16)30320-4. View

4.
Chen Y, Lin H, Lin C, Turbat B, Wang K, Chung W . Bronchiectasis and increased risk of ischemic stroke: a nationwide population-based cohort study. Int J Chron Obstruct Pulmon Dis. 2017; 12:1375-1383. PMC: 5436772. DOI: 10.2147/COPD.S126102. View

5.
Mullerova H, Marshall J, De Nigris E, Varghese P, Pooley N, Embleton N . Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis. 2022; 16:17534666221113647. PMC: 9340406. DOI: 10.1177/17534666221113647. View